OSMF
MCID: ORL004
MIFTS: 51

Oral Submucous Fibrosis (OSMF) malady

Categories: Rare diseases, Gastrointestinal diseases, Oral diseases

Aliases & Classifications for Oral Submucous Fibrosis

Aliases & Descriptions for Oral Submucous Fibrosis:

Name: Oral Submucous Fibrosis 12 50 56 52 42 14 69
Oral Submucosal Fibrosis, Including of Tongue 12 69
Osmf 50 56
Oral Cavity Submucous Fibrosis 12
Oral Submucosal Fibrosis 12

Characteristics:

Orphanet epidemiological data:

56
oral submucous fibrosis
Age of onset: All ages;

Classifications:



External Ids:

Disease Ontology 12 DOID:5773
ICD10 33 K13.5
ICD9CM 35 528.8
MeSH 42 D009914
NCIt 47 C34866
SNOMED-CT 64 32883009
Orphanet 56 ORPHA357154
ICD10 via Orphanet 34 K13.5

Summaries for Oral Submucous Fibrosis

MalaCards based summary : Oral Submucous Fibrosis, also known as oral submucosal fibrosis, including of tongue, is related to squamous cell carcinoma and leukoplakia, and has symptoms including flexion contracture, narrow mouth and abnormality of the pharynx. An important gene associated with Oral Submucous Fibrosis is LOX (Lysyl Oxidase), and among its related pathways/superpathways are Pathways in cancer and Drug metabolism - cytochrome P450. The drugs Hyaluronic acid and Hydrocortisone have been mentioned in the context of this disorder. Affiliated tissues include tongue, skin and t cells, and related phenotypes are cardiovascular system and homeostasis/metabolism

Wikipedia : 71 Oral submucous fibrosis (OSMF or OSF) is a chronic, complex, premalignant ( 1% transformation risk )... more...

Related Diseases for Oral Submucous Fibrosis

Diseases related to Oral Submucous Fibrosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 66)
id Related Disease Score Top Affiliating Genes
1 squamous cell carcinoma 10.4
2 leukoplakia 10.4
3 oral squamous cell carcinoma 10.4
4 mucositis 10.3
5 oral leukoplakia 10.3
6 oral cancer 10.3
7 noonan syndrome 4 10.1 MMP2 TGFB1
8 thrombophlebitis migrans 10.1 GSTM1 TGFB1
9 lichen planus pigmentosus 10.1 CYP1A1 GSTM1 GSTT1
10 differentiated thyroid carcinoma 10.1 GSTM1 GSTT1
11 uvula cancer 10.1 CYP1A1 GSTM1 GSTT1
12 bone angioendothelial sarcoma 10.1 PTGS2 TGFB1 TIMP1
13 speech and communication disorders 10.0 MMP2 TGFB1 TIMP1
14 zika fever 10.0 MMP2 TGFB1 TIMP1
15 angiomyoma 10.0 MMP2 TIMP1
16 central nervous system teratoma 10.0 LOX MMP2 TIMP1
17 osteonecrosis 10.0 PTGS2 TGFB1 TIMP1
18 acute necrotizing encephalitis 10.0 CDH1 PTGS2 TGFB1
19 hepatic flexure cancer 10.0 GSTM1 GSTT1 MMP2
20 chondrodysplasia punctata, rhizomelic, type 1 10.0 CDH1 PTGS2 TIMP1
21 burns 10.0
22 verrucous carcinoma 10.0
23 pemphigus 10.0
24 appendix carcinoid tumor 10.0 MMP2 TIMP1
25 adult neuronal ceroid lipofuscinosis 9.9 CDH1 MMP2 PTGS2
26 immune system disease 9.9 GSTM1 GSTT1 MMP2 PTGS2
27 maxillary neoplasm 9.9 CDH1 MMP2 TIMP1
28 pemphigus vulgaris 9.9
29 papilloma 9.9
30 gingivitis 9.9
31 burning mouth syndrome 9.9
32 breast papillary carcinoma 9.9 CDH1 MMP2 TIMP1
33 pulmonary fibrosis and/or bone marrow failure, telomere-related, 1 9.9 CDH1 MMP2 PTGS2
34 nodular cutaneous amyloidosis 9.9 CDH1 MMP2 TIMP1
35 malignant pleural solitary fibrous tumor 9.9 CDH1 MMP2 PTGS2
36 schwannomatosis 9.9 MMP2 TIMP1
37 rapsn-related fetal akinesia deformation sequence 9.9 CDH1 CYP1A1 GSTM1 GSTT1
38 nevoid hypermelanosis, linear and whorled 9.9 CDH1 MMP2 PTGS2
39 placenta praevia 9.9 CDH1 GSTM1 GSTT1 PTGS2
40 in situ pulmonary adenocarcinoma 9.8 CDH1 MMP2 PTGS2 TGFB1
41 proctitis 9.8 CDH1 MMP2 PTGS2 TGFB1
42 ocular melanoma 9.8 CDH1 CYP1A1 MMP2 PTGS2
43 muscle hypertrophy 9.8
44 adenomatous polyposis coli 9.8
45 deficiency anemia 9.8
46 disseminated intravascular coagulation 9.8
47 iron deficiency anemia 9.8
48 ankylosis 9.8
49 laryngitis 9.8
50 cellulitis 9.8

Graphical network of the top 20 diseases related to Oral Submucous Fibrosis:



Diseases related to Oral Submucous Fibrosis

Symptoms & Phenotypes for Oral Submucous Fibrosis

Human phenotypes related to Oral Submucous Fibrosis:

56 32 (show all 7)
id Description HPO Frequency Orphanet Frequency HPO Source Accession
1 flexion contracture 56 32 Frequent (79-30%) HP:0001371
2 narrow mouth 56 32 Very frequent (99-80%) HP:0000160
3 abnormality of the pharynx 56 32 Very frequent (99-80%) HP:0000600
4 cheilitis 56 32 Very frequent (99-80%) HP:0100825
5 trismus 56 32 Frequent (79-30%) HP:0000211
6 abnormality of the oral cavity 56 32 Very frequent (99-80%) HP:0000163
7 oropharyngeal squamous cell carcinoma 56 32 Occasional (29-5%) HP:0012182

UMLS symptoms related to Oral Submucous Fibrosis:


oral manifestations

MGI Mouse Phenotypes related to Oral Submucous Fibrosis:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.02 MMP2 PTGS2 SFRP4 TGFB1 TIMP1 CDH1
2 homeostasis/metabolism MP:0005376 9.97 CYP1A1 LOX MMP2 PTGS2 SFRP4 TGFB1
3 immune system MP:0005387 9.86 CDH1 COL1A1 CYP1A1 MMP2 PTGS2 SFRP4
4 mortality/aging MP:0010768 9.81 CDH1 COL1A1 CYP1A1 LOX MMP2 PTGS2
5 neoplasm MP:0002006 9.43 CDH1 COL1A1 MMP2 PTGS2 TGFB1 TIMP1
6 respiratory system MP:0005388 9.17 COL1A1 LOX MMP2 PTGS2 SFRP4 TGFB1

Drugs & Therapeutics for Oral Submucous Fibrosis

Drugs for Oral Submucous Fibrosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 29)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Hyaluronic acid Approved, Vet_approved Phase 3 9004-61-9 53477741 24759
2
Hydrocortisone Approved, Vet_approved Phase 3 50-23-7 5754 657311
3
Butyric Acid Experimental Phase 3 107-92-6 264
4 Adjuvants, Immunologic Phase 3
5 Anti-Inflammatory Agents Phase 3,Phase 2
6 Antioxidants Phase 3
7 Cortisol succinate Phase 3
8 Hydrocortisone 17-butyrate 21-propionate Phase 3
9 Hydrocortisone acetate Phase 3
10 Hydrocortisone-17-butyrate Phase 3
11 Protective Agents Phase 3
12 Viscosupplements Phase 3
13
Benzocaine Approved Phase 2 1994-09-7, 94-09-7 2337
14
Cisplatin Approved Phase 2 15663-27-1 84093 441203 2767
15 Tegafur Approved Phase 2 17902-23-7
16 tannic acid Approved, Nutraceutical Phase 2
17
leucovorin Approved, Nutraceutical Phase 2 58-05-9 54575, 6560146 143
18 Analgesics Phase 2
19 Analgesics, Non-Narcotic Phase 2
20 Anti-Inflammatory Agents, Non-Steroidal Phase 2
21 Antirheumatic Agents Phase 2
22
Curcumin Phase 2 458-37-7 969516
23 Peripheral Nervous System Agents Phase 2
24 Antimetabolites Phase 2
25 Antimetabolites, Antineoplastic Phase 2
26 Astragalus Nutraceutical Phase 2
27 Antibodies
28 Autoantibodies
29 Immunoglobulins

Interventional clinical trials:


id Name Status NCT ID Phase
1 Evaluation of Efficacy of Aloevera in the Treatment of Oral Submucous Fibrosis- A Clinical Study Completed NCT02714543 Phase 3
2 Topical Application of Curcumin Orabase in Oral Submucous Fibrosis (OSMF) Active, not recruiting NCT02645656 Phase 2
3 A Phase II Trial of PG2 in Patients With Advanced Pharyngeal or Laryngeal Squamous Cell Carcinoma Under Concurrent Chemoradiotherapy Terminated NCT01720563 Phase 2
4 Use of Single Staged Nasolabial Flap in Oral Submucous Fibrosis Completed NCT02711046
5 Evaluation of Auto Antibodies in Oral Sub Mucous Fibrosis Recruiting NCT03011086
6 Evaluation of Functional Dimensions of Macintosh Laryngoscope Blade During Direct Laryngoscopy in Patients With Normal Mouth Opening Recruiting NCT02639897

Search NIH Clinical Center for Oral Submucous Fibrosis

Cochrane evidence based reviews: oral submucous fibrosis

Genetic Tests for Oral Submucous Fibrosis

Anatomical Context for Oral Submucous Fibrosis

MalaCards organs/tissues related to Oral Submucous Fibrosis:

39
Tongue, Skin, T Cells, Testes, Endothelial, Liver, Salivary Gland

Publications for Oral Submucous Fibrosis

Articles related to Oral Submucous Fibrosis:

(show top 50) (show all 507)
id Title Authors Year
1
Breath Alkane as an index of severity for oral submucous fibrosis: A new perspective? ( 28012596 )
2017
2
Expression pattern of DKK3, dickkopf WNT signaling pathway inhibitorA 3, in the malignant progression of oral submucous fibrosis. ( 27959428 )
2017
3
MALDI imaging reveals NCOA7 as a potential biomarker in oral squamous cell carcinoma arising from oral submucous fibrosis. ( 27509054 )
2016
4
Omega 3: a novel treatment agent in oral submucous fibrosis: a pilot study. ( 28027413 )
2016
5
Oral epithelial dysplasia in oral submucous fibrosis: A challenge. ( 26778245 )
2016
6
Oral submucous fibrosis: a historical perspective and a review on etiology and pathogenesis. ( 27422417 )
2016
7
Versatility of nasolabial flaps for the management of severe trismus in oral submucous fibrosis. ( 27966506 )
2016
8
Roles of CYP1A1 and CYP2E1 Gene Polymorphisms in Oral Submucous Fibrosis. ( 27509973 )
2016
9
Proteomic identification of cyclophilin A as a potential biomarker and therapeutic target in oral submucous fibrosis. ( 27533088 )
2016
10
Augmentation of oral submucous fibrosis by NSAIDs in the presence of risk factors. ( 27087073 )
2016
11
Effect of curcumin on the expression of p53, transforming growth factor-I^, and inducible nitric oxide synthase in oral submucous fibrosis: A pilot study. ( 27989010 )
2016
12
"Oral Submucous Fibrosis Scoring Index" to Predict the Treatment Algorithm in Oral Submucous Fibrosis. ( 26929548 )
2016
13
Oral Submucous Fibrosis Secondary to Iron Deficiency Anemia: A Case Report, Etiopathogenesis and Management. ( 26812518 )
2016
14
Dental Informatics tool "SOFPRO" for the study of oral submucous fibrosis. ( 27601808 )
2016
15
Prognostic potential of AgNORs in oral submucous fibrosis. ( 27114958 )
2016
16
Identification of a combined biomarker for malignant transformation in oral submucous fibrosis. ( 27497264 )
2016
17
Effectiveness of Long Term Supervised and Assisted Physiotherapy in Postsurgery Oral Submucous Fibrosis Patients. ( 27885345 )
2016
18
Rebamipide to Manage Stomatopyrosis in Oral Submucous Fibrosis. ( 27965488 )
2016
19
Clinical Efficacy of a Mouth-Exercising Device Adjunct to Local Ointment Intra-Lesional Injections and Surgical Treatment for Oral Submucous Fibrosis: a Randomized Controlled Trial. ( 27039756 )
2016
20
Oral submucous fibrosis: a review of the current management and possible directions for novel therapies. ( 27422422 )
2016
21
Efficacy of buccal fat pad in the surgical management of oral submucous fibrosis: a prospective study. ( 26768398 )
2016
22
Autophagy mediates oral submucous fibrosis. ( 27168817 )
2016
23
Surgical defect coverage in oral submucous fibrosis patients with single-stage extended nasolabial flap. ( 27663242 )
2016
24
Introduction to the Oral and Maxillofacial Pathology focus issue on oral submucous fibrosis. ( 27422415 )
2016
25
An Innovative Approach to Evaluate the Morphological Patterns of Soft Palate in Oral Submucous Fibrosis Patients: A Digital Cephalometric Study. ( 27034975 )
2016
26
Assessment of Function of Eustachian Tube in Oral Submucous Fibrosis - A Tympanometric Study. ( 27790571 )
2016
27
Clinically malignant exophytic lesions in the background of oral submucous fibrosis: report of five cases. ( 27422419 )
2016
28
Aberrant SSEA-4 upregulation mediates myofibroblast activity to promote pre-cancerous oral submucous fibrosis. ( 27845370 )
2016
29
Qualitative Analysis of Collagen Fibers in Oral Submucous Fibrosis using Picrosirius Red Stain and Polarising Microscope. ( 27042575 )
2016
30
Evaluation of Internal Echogenic Pattern of Masseter in Subjects with Myofascial Pain/ Myositis, Oral Submucous Fibrosis, Chewers, Bruxers and Healthy Individuals- A Preliminary Ultrasonographic Study. ( 27942553 )
2016
31
Myofibroblasts could be recruited in a Chemokine (C-C motif) Ligand 2-dependant manner in pathogenesis of oral submucous fibrosis. ( 28029690 )
2016
32
A preliminary microarray assay of the miRNA expression signatures in buccal mucosa of oral submucous fibrosis patients. ( 26991343 )
2016
33
A Rare Case of Tamarind Seed Induced Oral Submucous Fibrosis in a 12-Year-Old Indian Boy. ( 27504424 )
2016
34
Evaluation of transforming growth factor beta1 gene in oral submucous fibrosis induced in Sprague-Dawley rats by injections of areca nut and pan masala (commercial areca nut product) extracts. ( 27072267 )
2016
35
Characterization of a Novel Dermal Fibrosis Model Induced by Areca Nut Extract that Mimics Oral Submucous Fibrosis. ( 27851781 )
2016
36
Quantitative proteomic analysis for novel biomarkers of buccal squamous cell carcinoma arising in background of oral submucous fibrosis. ( 27485544 )
2016
37
Malignant transformation of oral submucous fibrosis: overview of histopathological aspects. ( 27422418 )
2016
38
Letter to Editor: 'Lactate dehydrogenase as a biomarker in oral cancer and oral submucous fibrosis'. ( 27612179 )
2016
39
Response to Oral epithelial dysplasia in oral submucous fibrosis: A challenge. ( 26786963 )
2016
40
Aggrandizing oral submucous fibrosis grading using an adjunct special stain: A pilot study. ( 27194860 )
2016
41
Comment on "Facial Atrophy in Oral Submucous Fibrosis: An Association or a Coincidence". ( 27891262 )
2016
42
Bipaddled anterolateral thigh perforator flap for simultaneous reconstruction of bilateral buccal defects following oral cancer ablation or release of oral submucous fibrosis. ( 27619322 )
2016
43
Is there an association between oral submucous fibrosis and ABO blood grouping? ( 27072224 )
2016
44
Effectiveness of Aloe Vera and Antioxidant along with Physiotherapy in the Management of Oral Submucous Fibrosis. ( 27084867 )
2016
45
Facial Atrophy in Oral Submucous Fibrosis: An Association or a Coincidence. ( 27339711 )
2016
46
Matrix metalloproteinases-3 gene-promoter polymorphism as a risk factor in oral submucous fibrosis in an Indian population: a pilot study. ( 27389714 )
2016
47
Comparison of Therapeutic Efficacy of Placental Extract with Dexamethasone and Hyaluronic Acid with Dexamethasone for Oral Submucous Fibrosis - A Retrospective Analysis. ( 27891461 )
2016
48
A rat model of oral submucous fibrosis induced by bleomycin. ( 27422420 )
2016
49
Immunohistochemical study of p21 and Bcl-2 in leukoplakia, oral submucous fibrosis and oral squamous cell carcinoma. ( 27849339 )
2016
50
Intralesional corticosteroids as a treatment for restricted mouth opening in oral submucous fibrosis. ( 27422421 )
2016

Variations for Oral Submucous Fibrosis

Expression for Oral Submucous Fibrosis

Search GEO for disease gene expression data for Oral Submucous Fibrosis.

Pathways for Oral Submucous Fibrosis

Pathways related to Oral Submucous Fibrosis according to GeneCards Suite gene sharing:

(show all 17)
id Super pathways Score Top Affiliating Genes
1 12.41 CDH1 MMP2 PTGS2 TGFB1
2
Show member pathways
12.38 CYP1A1 GSTM1 GSTT1 PTGS2
3 11.86 GSTM1 GSTT1 MMP2
4 11.84 CDH1 MMP2 PTGS2 TGFB1
5
Show member pathways
11.75 CDH1 COL1A1 LOX MMP2 TGFB1 TIMP1
6 11.63 COL1A1 MMP2 TGFB1
7 11.61 MMP2 PTGS2 TGFB1 TIMP1
8
Show member pathways
11.51 CYP1A1 GSTM1 GSTT1
9 11.38 MMP2 TGFB1 TIMP1
10 11.33 COL1A1 MMP2 TIMP1
11 11.2 MMP2 PTGS2 TGFB1 TIMP1
12
Show member pathways
11.1 CYP1A1 GSTM1
13 11.08 MMP2 TGFB1
14 11.01 GSTM1 GSTT1
15 10.78 CDH1 TGFB1
16 10.71 CYP1A1 GSTM1 GSTT1
17 10.65 GSTT1 PTGS2

GO Terms for Oral Submucous Fibrosis

Cellular components related to Oral Submucous Fibrosis according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.87 CDH1 COL1A1 LOX MMP2 SFRP4 TGFB1
2 extracellular space GO:0005615 9.73 COL1A1 LOX MMP2 SFRP4 TGFB1 TIMP1
3 extracellular matrix GO:0031012 9.46 COL1A1 MMP2 TGFB1 TIMP1
4 collagen trimer GO:0005581 9.13 COL1A1 LOX TIMP1
5 proteinaceous extracellular matrix GO:0005578 9.02 COL1A1 LOX MMP2 TGFB1 TIMP1

Biological processes related to Oral Submucous Fibrosis according to GeneCards Suite gene sharing:

(show all 22)
id Name GO ID Score Top Affiliating Genes
1 extracellular matrix organization GO:0030198 9.77 CDH1 COL1A1 LOX
2 response to hypoxia GO:0001666 9.76 CYP1A1 MMP2 TGFB1
3 response to organic cyclic compound GO:0014070 9.72 CYP1A1 PTGS2 TGFB1
4 response to estradiol GO:0032355 9.67 COL1A1 PTGS2 TGFB1
5 extracellular matrix disassembly GO:0022617 9.65 CDH1 MMP2 TIMP1
6 cellular response to mechanical stimulus GO:0071260 9.63 COL1A1 PTGS2 TGFB1
7 aging GO:0007568 9.62 CYP1A1 PTGS2 TGFB1 TIMP1
8 digestive tract development GO:0048565 9.61 CYP1A1 TGFB1
9 positive regulation of vascular endothelial growth factor production GO:0010575 9.59 PTGS2 TGFB1
10 response to immobilization stress GO:0035902 9.58 CYP1A1 TGFB1
11 glutathione derivative biosynthetic process GO:1901687 9.57 GSTM1 GSTT1
12 response to vitamin D GO:0033280 9.56 PTGS2 TGFB1
13 response to hyperoxia GO:0055093 9.54 COL1A1 CYP1A1
14 response to hormone GO:0009725 9.54 LOX SFRP4 TIMP1
15 cell activation GO:0001775 9.52 TGFB1 TIMP1
16 negative regulation of cell-cell adhesion GO:0022408 9.51 CDH1 TGFB1
17 wound healing GO:0042060 9.46 COL1A1 LOX TGFB1 TIMP1
18 bone trabecula formation GO:0060346 9.43 COL1A1 MMP2
19 face morphogenesis GO:0060325 9.43 COL1A1 MMP2 TGFB1
20 response to drug GO:0042493 9.43 CDH1 COL1A1 CYP1A1 LOX PTGS2 TGFB1
21 intramembranous ossification GO:0001957 9.4 COL1A1 MMP2
22 response to organic substance GO:0010033 9.02 CDH1 CYP1A1 PTGS2 TGFB1 TIMP1

Molecular functions related to Oral Submucous Fibrosis according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 glutathione transferase activity GO:0004364 8.96 GSTM1 GSTT1
2 enzyme binding GO:0019899 8.92 CYP1A1 GSTM1 PTGS2 TGFB1

Sources for Oral Submucous Fibrosis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....